Lisa Lancaster

New drugs approved to fight idiopathic pulmonary fibrosis

The Vanderbilt Idiopathic Pulmonary Fibrosis Center played a key role in testing the first two drugs approved by the FDA for the treatment of idiopathic pulmonary fibrosis (IPF).

man wearing cpap

Study examines sleep apnea’s role in lung diseases

Vanderbilt’s idiopathic pulmonary fibrosis research group is embarking on a study to determine the prevalence of sleep apnea in people with other interstitial lung diseases.

X-ray of lungs

Lung disorder drug regimen found harmful

Longtime treatment for IPF ineffective and even dangerous.